Thermo Fisher Scientific Inc. Q1 2026 Earnings Recap

TMO Q1 2026 April 23, 2026

Get alerts when TMO reports next quarter

Thermo Fisher delivered a robust Q1 with 6% revenue growth to $11.01 billion, driven by strength in biotech and pharma markets, while maintaining disciplined margins and expanding innovative offerings.

Earnings Per Share Beat

$5.44 vs $5.25 est.

+3.6% surprise

Revenue Beat

11005000000 vs 10864750000 est.

+1.3% surprise

Market Reaction

1-Day -8.61%

5-Day -8.51%

30-Day -14.72%

See TMO alongside your other holdings

Add to your portfolio — free

Key Takeaways

Revenue increased 6% to $11.01 billion; adjusted EPS up 6% to $5.44, supported by a 21.8% operating margin.
Pharma and biotech markets grew mid-single-digit, led by bioproduction, clinical research, and safety channels.
Launches included advanced cryo-EM and mass spectrometry solutions, reinforcing industry leadership and customer value.
Strategic collaborations with NVIDIA and SHL Medical enhance AI-driven workflows and manufacturing capabilities.
End markets are expected to remain resilient amid macroeconomic uncertainties and ongoing innovation efforts.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit TMO on AllInvestView.

Previous Q3 2025